NCT05771480 2026-04-21
TOURMALINE
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT06467357 2026-04-16
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT06282575 2026-03-24
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT07221253 2026-03-17
AB02
AstraZeneca
Phase 3 Recruiting
NCT06109779 2026-03-04
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Phase 3 Active not recruiting
NCT06591520 2026-01-21
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Akeso
Phase 3 Active not recruiting
NCT07062263 2025-07-14
TAB-2
Tata Memorial Centre
Phase 3 Recruiting
NCT03478488 2025-05-29
KN035-BTC
3D Medicines
Phase 3 Active not recruiting
NCT05615818 2025-04-23
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT03673072 2024-11-12
GAIN
Krankenhaus Nordwest
Phase 3 Completed
NCT04163900 2023-05-24
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Phase 3 Terminated
NCT04401709 2022-06-15
Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer
Samsung Medical Center
Phase 3 Unknown
NCT02182778 2019-02-21
GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
Phase 3 Completed